Targeting ROR1 inhibits the self-renewal and invasive ability of glioblastoma stem cells

Cell Biochemistry and Function

Volumn 34, Issue 3, 2016, Pages 149-157

  Jung, Eun Hwa ^a   Lee, Han Na ^a   Han, Gi Yeon ^a   Kim, Min Jung ^a,b   Kim, Chan Wha ^a  

^a Korea University   (South Korea)

^b National Institute of Food and Drug Safety Evaluation   (South Korea)

Author keywords

Glioblastoma stem cells; Invasion; Migration; ROR1; Stemness

Indexed keywords

CD133 ANTIGEN; MESSENGER RNA; NESTIN; NOTCH1 RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; ROR1 PROTEIN, HUMAN;

ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL SELF-RENEWAL; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; METASTASIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; BRAIN NEOPLASMS; DEFICIENCY; GENE SILENCING; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL CULTURE; TUMOR INVASION;

BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL SELF RENEWAL; DOWN-REGULATION; GENE SILENCING; GLIOBLASTOMA; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; TUMOR CELLS, CULTURED;

EID: 84959386471     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.3172     Document Type: Article

References (35)

1. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013; 310: 1842-1850 1764056 [pii]. doi:10.1001/jama.2013.280319.
2. Westphal M, Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci 2011; 12: 495-508 nrn3060 [pii]. doi:10.1038/nrn3060.
3. Foty RA. Tumor cohesion and glioblastoma cell dispersal. Future Oncol 2013; 9: 1121-1132. doi:10.2217/Fon.13.66.
4. Persano L, Rampazzo E, Basso G, Viola G. Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting. Biochem Pharmacol 2013; 85: 612-622 DOI: S0006-2952(12)00665-X [pii]. doi:10.1016/j.bcp.2012.10.001.
5. Vermeulen L, de Sousa Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012; 13: e83-e89 S1470-2045(11)70257-1 [pii]. doi:10.1016/S1470-2045(11)70257-1.
6. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007; 369: 1742-1757 S0140-6736(07)60781-8 [pii]. doi:10.1016/S0140-6736(07)60781-8.
7. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-1784. doi:10.1172/JCI20530 112/12/1776 [pii].
8. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454. doi:10.1038/nrc822 nrc822 [pii].
9. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890 S0092-8674(09)01419-6 [pii]. doi:10.1016/j.cell.2009.11.007.
10. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715 S0092-8674(08)00444-3 [pii]. doi:10.1016/j.cell.2008.03.027.
11. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008; 3: e2888. doi:10.1371/journal.pone.0002888.
12. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273. doi:10.1038/Nrc2620.
13. Scheel C, Eaton EN, Li SH, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011; 145: 926-940 S0092-8674(11)00525-3 [pii]. doi:10.1016/j.cell.2011.04.029.
14. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-1495 ncb1998 [pii]. doi:10.1038/ncb1998.
15. Green JL, Kuntz SG, Sternberg PW. Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol 2008; 18: 536-544 S0962-8924(08)00236-5 [pii]. doi:10.1016/j.tcb.2008.08.006.
16. Fukuda T, Chen L, Endo T, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A 2008; 105: 3047-3052 0712148105 [pii]. doi:10.1073/pnas.0712148105.
17. Cui B, Zhang S, Chen L, et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res 2013; 73: 3649-3660 73/12/3649 [pii]. doi:10.1158/0008-5472.CAN-12-3832.
18. Zhang S, Cui B, Lai H, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A 2014; 111: 17266-17271 1419599111 [pii]. doi:10.1073/pnas.1419599111.
19. Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, et al. The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol 2014; 29: 21-31 S1044-579X(14)00093-5 [pii]. doi:10.1016/j.semcancer.2014.07.005.
20. Kim MJ, Lee YS, Han GY, Lee HN, Ahn C, Kim CW. Profilin 2 promotes migration, invasion, and stemness of HT29 human colorectal cancer stem cells. Biosci Biotechnol Biochem 2015; 1-9. doi:10.1080/09168451.2015.1043118.
21. Chen X, Chen L, Chen J, et al. ADAM17 promotes U87 glioblastoma stem cell migration and invasion. Brain Res 2013; 1538: 151-158.
22. Moon SH, Park KS. Enrichment of Cancer Stem Cell of Glioblastoma by Neurosphere Formation. Tissue Engineering and Regenerative Medicine 2012; 9: 270-277.
23. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110 nature05372 [pii]. doi:10.1038/nature05372.
24. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401 nature03128 [pii]. doi:10.1038/nature03128.
25. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008; 68: 9703-9711 68/23/9703 [pii]. doi:10.1158/0008-5472.CAN-08-3084.
26. Qiang L, Yang Y, Ma YJ, et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 2009; 279: 13-21 S0304-3835(09)00034-2 [pii]. doi:10.1016/j.canlet.2009.01.016.
27. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 2008; 123: 1190-1195. doi:10.1002/ijc.23587.
28. Hojjat-Farsangi M, Ghaemimanesh F, Daneshmanesh AH, et al. Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells. PLoS One 2013; 8 ARTN: e61167. doi:10.1371/journal.pone.0061167.
29. Rabbani H, Ostadkarampour M, Danesh Manesh AH, Basiri A, Jeddi-Tehrani M, Forouzesh F. Expression of ROR1 in patients with renal cancer--a potential diagnostic marker. Iran Biomed J 2010; 14: 77-82.
30. Shabani M, Asgarian-Omran H, Jeddi-Tehrani M, et al. Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour Biol 2007; 28: 318-326 000121405 [pii]. doi:10.1159/000121405.
31. Yamaguchi T, Yanagisawa K, Sugiyama R, et al. NKX2-1/TITF1/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 2012; 21: 348-361. doi:10.1016/j.ccr.2012.02.008.
32. Zhang SP, Chen LG, Cui B, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One 2012; 7 ARTN e31127. doi:10.1371/journal.pone.0031127.
33. Endo M, Doi R, Nishita M, Minami Y. Ror family receptor tyrosine kinases regulate the maintenance of neural progenitor cells in the developing neocortex. J Cell Sci 2012; 125: 2017-2029 jcs.097782 [pii]. doi:10.1242/jcs.097782.
34. Yoon C-H, Hyun K-H, Kim R-K, et al. The small GTPase Rac1 is involved in the maintenance of stemness and malignancies in glioma stem-like cells. FEBS Lett 2011; 585: 2331-2338.
35. Balbous A, Cortes U, Guilloteau K, et al. A mesenchymal glioma stem cell profile is related to clinical outcome. Oncogenesis 2014; 3: e91 oncsis20145 [pii]. doi:10.1038/oncsis.2014.5.